Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 101–200 of 1,000
Yu, Y. H., Song, M., Chen, C., Du, Y., Li, C., Han, Y., Yan, F., Shi, Z., & Feng, S. (2020) · ACS Nano · doi:10.1021/acsnano.0c05332 · Cited by 143
Co-evolution of tumor and immune cells during progression of multiple myeloma
Liu, R., Gao, Q., Foltz, S. M., Fowles, J. S., Yao, L., Wang, J. T., Cao, S., Sun, H., Wendl, M. C., Sethuraman, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22804-x · Cited by 133
“4), (3) detecting CNV based on normalized data (NBICseqseg_v0.”
BackgroundDimopoulos, M. A., Lonial, S., White, D., Moreau, P., Palumbo, A., San‐Miguel, J., Shpilberg, O., Anderson, K., Grosicki, S., Spicka, I., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14787 · Cited by 135
Self-citationCancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Facon, T., Lee, J. H., Moreau, P., Niesvizky, R., Dimopoulos, M., Hajek, R., Pour, L., Jurczyszyn, A., Qiu, L., Klippel, Z., et al. (2019) · Blood · doi:10.1182/blood-2018-09-874396 · Cited by 128
Self-citationBiology and therapy of multiple myeloma
Joshua, D., Bryant, C. E., Dix, C. H. K., Gibson, J., & Ho, P. J. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50129 · Cited by 143
Avet-Loiseau, H., Ludwig, H., Landgren, O., Paiva, B., Morris, C., Yang, H., Zhou, K., Ro, S., & Mateos, M.-V. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.622 · Cited by 134
Self-citationCardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies
Georgiopoulos, G. A., Makris, N., Laina, A., Theodorakakou, F., Briasoulis, Α., Trougakos, I. P., Dimopoulos, M. A., Kastritis, E., & Stamatelopoulos, K. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.12.005 · Cited by 144
“The randomized phase 3 study ENDEAVOR (Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients) compared the combination of bortezomib and dexamethasone (Vd) to carfilzomib and dexamethasone (Kd) in RRMM patients and showed significant improvement in…”
BackgroundInfluentialSelf-citationRichardson, P. G., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2016) · Blood · doi:10.1182/blood-2015-09-665018 · Cited by 131
Self-citationTocchetti, C. G., Dessalvi, C. C., Lisi, D. D., Femminò, S., Madonna, R., Mele, D., Monte, I. P., Novo, G., Penna, C. R. R., Pepe, A., et al. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6930 · Cited by 143
Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors
Sogbein, O., Paul, P., Umar, M., Châari, A., Batuman, V., & Upadhyay, R. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123125 · Cited by 135
Avet‐Loiseau, H., Fonseca, R., Siegel, D. S. D., Dimopoulos, M. A., Špıčka, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V. S., Mihaylov, G. G., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707596 · Cited by 131
Self-citationvan Beurden-Tan, C. H. Y., Franken, M. G., Blommestein, H. M., Groot, C. A. U., & Sonneveld, P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1663 · Cited by 132
Tundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 126
Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A. P., Rosiñol, L., Nagler, A., Yong, K., Oriol, A., Minařík, J., Pour, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.176 · Cited by 122
Self-citationPaediatric cardio-oncology: epidemiology, screening, prevention, and treatment
Chow, E. J., Leger, K. J., Bhatt, N. S., Mulrooney, D. A., Ross, C. J., Aggarwal, S. A., Bansal, N., Ehrhardt, M. J., Armenian, S. H., Scott, J. M., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz031 · Cited by 129
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelínek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 124
Self-citationManagement of multiple myeloma in the relapsed/refractory patient
Sonneveld, P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.508 · Cited by 107
Resistance to proteasome inhibitors and other targeted therapies in myeloma
Wallington-Beddoe, C. T., Sobieraj‐Teague, M., Kuss, B. J., & Pitson, S. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15210 · Cited by 118
Glucocorticoids in multiple myeloma: past, present, and future
Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 122
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“Myeloma Lenalidomide + dexamethasone+ carfilzomib [103]; Lenalidomide + dexamethasone [104, 105]”
BackgroundSelf-citationChari, A., Romanus, D., Palumbo, A. P., Blazer, M. A., Farrelly, E., Raju, A., Huang, H., & Richardson, P. G. G. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.625 · Cited by 113
Self-citationThe ubiquitin–proteasome system in breast cancer
Han, D., Wang, L., Jiang, S., & Yang, Q. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.05.006 · Cited by 115
Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D’Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0142-9 · Cited by 114
Self-citationCardiac and renal complications of carfilzomib in patients with multiple myeloma
Dimopoulos, M. A., Ρούσσου, Μ., Gavriatopoulou, M., Psimenou, E., Ziogas, D. C., Eleutherakis‐Papaiakovou, E., Fotiou, D., Migkou, M., Kanellias, N., Panagiotidis, I., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003269 · Cited by 110
Self-citationManagement of cardiovascular risk in patients with multiple myeloma
Plummer, C., Driessen, C., Szabó, Z. R., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0183-y · Cited by 115
Self-citationBispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J., Sanchez, L., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 98
Ludwig, H., Delforge, M., Facon, T. T. F., Einsele, H., Gay, F., Moreau, P., Avet‐Loiseau, H., Boccadoro, M., Hájek, R., Mohty, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0040-1 · Cited by 104
“5% of relapsed/refractory myeloma exposed to carfilzomib– lenalidomide–dexamethasone [74].”
BackgroundSelf-citationCornell, R. F., & Kassim, A. A. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.307 · Cited by 100
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review
Li, W., Garcia, D. A., Cornell, R. F., Gailani, D., Laubach, J. P., Maglio, M. E., Richardson, P. G. G., & Moslehi, J. J. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3350 · Cited by 109
Bringhen, S., Milan, A., Ferri, C., Wäsch, R., Gay, F., Larocca, A., Salvini, M., Terpos, E., Goldschmidt, H., Cavo, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191288 · Cited by 106
Self-citationJayaweera, S. P. E., Kanakanamge, S. P. W., Rajalingam, D., & Silva, G. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740796 · Cited by 107
“Adverse Events ASPIRE trial (93) ENDEAVOR trial (88, 94)”
BackgroundMethodEfficace, F., Gaïdano, G., & Lo‐Coco, F. (2017) · Blood · doi:10.1182/blood-2017-03-737403 · Cited by 98
Vasyuk, Y. A., Gendlin, G. E., Emelina, E. I., Shupenina, E. Y., Ballyuzek, M. F., Баринова, И. В., Vitsenya, M. V., Davydkin, I. L., Петрович, Д. Д., Duplyakov, D. V., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4703 · Cited by 98
Mazzotti, C., Buisson, L., Mahéo, S., Perrot, A., Chrétien, M., Leleu, X. P., Hulin, C., Manier, S., Hébraud, B., Roussel, M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018025197 · Cited by 104
Berenson, J. R., Cartmell, A., Bessudo, A., Lyons, R. M., Harb, W., Tzachanis, D., Agajanian, R., Boccia, R., Coleman, M., Moss, R. A., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683854 · Cited by 94
Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management
Wu, P., Oren, O., Gertz, M. A., & Yang, E. H. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00931-w · Cited by 98
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Eleutherakis‐Papaiakovou, E., Kanellias, N., Kastritis, E., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2020) · Journal of Oncology · doi:10.1155/2020/7131802 · Cited by 97
Self-citationMagarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F. F., Mina, R., Falcone, A. P., Paoli, L. D., Pietrantuono, G., Gentili, S., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662627 · Cited by 93
Self-citationAnderson, K. C., Auclair, D., Kelloff, G. J., Sigman, C. C., Avet-Loiseau, H., Farrell, A. T., Gormley, N. J., Kumar, S. K., Landgren, O., Munshi, N. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2895 · Cited by 91
“the recent ASPIRE trial (85), making future trials targeting PFS long, complicated, and costly.”
BackgroundBockstahler, M., Fischer, A., Goetzke, C. C., Neumaier, H. L., Sauter, M., Kespohl, M., Müller, A.-M., Meckes, C., Salbach, C., Schenk, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043171 · Cited by 92
Ettari, R., Zappalà, M., Grasso, S., Musolino, C., Innao, V., & Allegra, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.09.001 · Cited by 96
Carfilzomib for relapsed and refractory multiple myeloma
Groen, K., van de Donk, N. W. C. J., Stege, C. A. M., Zweegman, S., & Nijhof, I. S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s150653 · Cited by 89
Role of Proteasomes in Inflammation
Goetzke, C. C., Ebstein, F., & Kallinich, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081783 · Cited by 82
How I treat myeloma with new agents
Moreau, P. (2017) · Blood · doi:10.1182/blood-2017-05-743203 · Cited by 94
Self-citationEmerging agents and regimens for multiple myeloma
Yang, Y., Li, Y., Gu, H., Dong, M., & Cai, Z. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00980-5 · Cited by 88
“In the ASPIRE (NCT01080391) study [22], compared with Len plus DEX (RD), addition of carfilzomib (KRD) achieved a higher rate of OS (87.”
BackgroundClinical pharmacokinetics and pharmacodynamics of lenalidomide
Chen, N., Zhou, S., & Palmisano, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0432-1 · Cited by 86
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
Hu, J., & Hu, W.-X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.020 · Cited by 84
Siegel, D. S., Schiller, G. J., Samaras, C., Sebag, M., Berdeja, J., Ganguly, S., Matous, J., Song, K., Seet, C. S., Talamo, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0813-1 · Cited by 83
Self-citationDanhof, S., Schreder, M., Rasche, L., Strifler, S., Einsele, H., & Knop, S. T. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12677 · Cited by 84
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis
Shah, C., Bishnoi, R., Jain, A., Bejjanki, H., Xiong, S., Wang, Y., Zou, F., & Moreb, J. S. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1437269 · Cited by 83
Chari, A., Stewart, A. K., Russell, S. D., Moreau, P., Herrmann, J., Banchs, J. A., Hájek, R., Groarke, J. D., Lyon, A. R., Batty, G. N., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015545 · Cited by 86
Self-citationRichardson, P. G. G., Zimmerman, T. M., Hofmeister, C. C., Talpaz, M., Chanan-Khan, A. A., Kaufman, J. L., Laubach, J. P., Chauhan, D., Jakubowiak, A. J., Reich, S. D., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686378 · Cited by 85
Self-citationNavigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt, H., Ashcroft, J., Szabo, Z., & Garderet, L. (2019) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 79
Repurposing anticancer drugs for the management of COVID-19
Bairi, K. E., Trapani, D., Petrillo, A., Page, C. L., Zbakh, H., Daniele, B., Belbaraka, R., Curigliano, G., & Afqir, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.014 · Cited by 83
Moreau, P., Joshua, D., Chng, W.-J., Palumbo, A., Goldschmidt, H., Hájek, R., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., et al. (2017) · Leukemia · doi:10.1038/leu.2016.186 · Cited by 78
Self-citationNext-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 84
Self-citationDamlaj, M., Fakih, R. O. E., & Hashmi, S. K. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.07.003 · Cited by 84
Second primary malignancies in multiple myeloma: A review
Poh, C., Keegan, T., & Rosenberg, A. S. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100757 · Cited by 73
Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A., Lust, J. A., et al. (2017) · Blood · doi:10.1182/blood-2017-05-782961 · Cited by 78
Self-citationStewart, A. K., Dimopoulos, M. A., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Niesvizky, R., Jakubowiak, A. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9648 · Cited by 84
Self-citationA systematic review of health‐related quality of life in longitudinal studies of myeloma patients
Nielsen, L. K., Jarden, M., Andersen, C. L., Frederiksen, H., & Abildgaard, N. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12882 · Cited by 79
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Rosenthal, A., Luthi, J., Belohlavek, M., Kortüm, K. M., Mookadam, F., Mayo, A., Fonseca, R., Bergsagel, P. L., Reeder, C. B., Mikhael, J. R., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2015.112 · Cited by 75
Self-citationNew investigational drugs with single-agent activity in multiple myeloma
Rajan, A. M., & Kumar, S. K. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.53 · Cited by 81
Myeloma Bone Disease: A Comprehensive Review
Mukkamalla, S. K. R., & Malipeddi, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126208 · Cited by 81
How I treat fragile myeloma patients
Larocca, A., & Palumbo, A. P. (2015) · Blood · doi:10.1182/blood-2015-05-612960 · Cited by 79
Self-citationMoreau, P., Dimopoulos, M. A., Yong, K., Mikhael, J. R., Risse, M., Asset, G., & Martin, T. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0431 · Cited by 76
Self-citationHeart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection
Hahn, V. S., Zhang, K. W., Sun, L., Narayan, V., Lenihan, D. J., & Ky, B. (2021) · Circulation Research · doi:10.1161/circresaha.121.318223 · Cited by 76
Spencer, A. G., Harrison, S. J., Zonder, J. A., Badros, A. Z., Laubach, J. P., Bergin, K., Khot, A. S., Zimmerman, T. M., Chauhan, D., Levin, N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14987 · Cited by 79
AL Amyloidosis for the Cardiologist and Oncologist
Witteles, R. M., & Liedtke, M. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.08.002 · Cited by 80
Richardson, P. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A.-M., Risse, M.-L., Corzo, K., & Anderson, K. C. (2018) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 70
Safety of proteasome inhibitors for treatment of multiple myeloma
Schlafer, D., Shah, K. S., Panjic, E. H., & Lonial, S. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1259310 · Cited by 71
“In both the ASPIRE and ENDEAVOR studies, cardiac-related deaths were similar between groups but overall cardiac adverse events were higher in patients receiving carfilzomib [46,53].”
BackgroundResultInfluentialMondala, P. K., Vora, A. A., Zhou, T., Lazzari, E., Ladel, L., Luo, X., Kim, Y., Costello, C. L., MacLeod, A. R., Jamieson, C. H. M., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2020.12.017 · Cited by 72
Rosiñol, L., Oriol, A., Teruel, A. I., de la Guía, A. L., Blanchard, M., de la Rubia, J., Granell, M., Sampol, M., Palomera, L., González, Y., et al. (2017) · Leukemia · doi:10.1038/leu.2017.35 · Cited by 71
Self-citationDimopoulos, M. A., Stewart, A. K., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Mihaylov, G. G., Goranova-Marinova, V. S., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14549 · Cited by 73
“In a pre-planned interim analysis of the ASPIRE trial, progression-free survival [PFS; hazard ratio (HR) = 0 69; P = 0 0001) and overall response rate (ORR; 87 1% vs. 66 7%; P < 0 001) were significantly higher in the carfilzomib group vs. the control group (Stewart et al, 2015).”
BackgroundMethodResultInfluentialSelf-citationCardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma
Cole, D. C., & Frishman, W. H. (2017) · Cardiology in Review · doi:10.1097/crd.0000000000000183 · Cited by 76
An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma
Silva, A., Silva, M. C., Sudalagunta, P. R., Graeter, A. I., Jacobson, T., Collins, A., Nguyen, T., Song, J., Chen, D., Chen, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0502 · Cited by 74
“Frontline therapy combining multiple novel agents, high-dose therapy with autologous stem cell transplant, and maintenance therapy has yielded a high success rate of response in multiple myeloma (7).”
A prospective, iterative, adaptive trial of carfilzomib-based desensitization
Tremblay, S., Driscoll, J. J., Shields, A. R., Hildeman, D. A., Alloway, R. R., Girnita, A. L., Brailey, P. A., & Woodle, E. S. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15613 · Cited by 73
Treatment and disease‐related complications in multiple myeloma: Implications for survivorship
Chakraborty, R., & Majhail, N. S. (2020) · American Journal of Hematology · doi:10.1002/ajh.25764 · Cited by 73
“RCTs have shown a higher rate of all-grade and ≥ grade 3 renal toxicities in carfilzomib arms compared to controls.(10,11,36,99) The majority of renal toxicities were classified as acute kidney injury (AKI).”
BackgroundResultA practical review on carfilzomib in multiple myeloma
Muchtar, E., Gertz, M. A., & Magen, H. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12749 · Cited by 72
“In the past year, more data have been published on carfilzomib in MM, including two large phase 3 studies (5, 6).”
BackgroundInfluentialSobh, M. A. K., Michallet, M., Gahrton, G., Iacobelli, S., van Biezen, A., Schönland, S. O., Petersen, E. J., Schaap, N. P., Bonifazi, F., Volin, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.101 · Cited by 71
Hou, J., Jin, J., Xu, Y., Wu, D., Ke, X., Zhou, D., Lu, J., Du, X., Chen, X., Li, J., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0501-4 · Cited by 71
Self-citationVogl, D. T., Martin, T. G., Vij, R., Hari, P., Mikhael, J. R., Siegel, D., Wu, K. L., Delforge, M., & Gasparetto, C. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2016.1263842 · Cited by 66
“In the interim, carfilzomib has clearly found a place in myeloma therapy, with demonstrated responses in relapsed/refractory patients as monotherapy[8] and a favorable toxicity and efficacy profile as a combination therapy in a randomized phase III trial.[9] The efficacy results for single-agent carfilzomib included a…”
ResultSelf-citationThe immunoproteasome‐specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis
Althof, N., Goetzke, C. C., Kespohl, M., Voss, K., Heuser, A., Pinkert, S., Kaya, Z., Klingel, K., & Beling, A. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708089 · Cited by 73
“First- and second-generation proteasome inhibitors, such as bortezomib and carfilzomib, are used for patients with multiple myeloma (Richardson et al, 2003, 2005; Stewart et al, 2015).”
BackgroundTreatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M.-V. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Self-citationDimopoulos, M. A., Stewart, A. K., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Mihaylov, G. G., Goranova‐Marinova, V., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.31 · Cited by 69
Self-citationHow I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre-Barbe, M., Lafon, I., Facon, T., Leleu, X., Karlin, L., Perrot, A., et al. (2018) · Blood · doi:10.1182/blood-2018-07-863829 · Cited by 65
Self-citationGoldschmidt, H., Baertsch, M., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M., Hillengaß, J., Sauer, S., Müller‐Tidow, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0948-0 · Cited by 70
Bispecific antibodies in multiple myeloma treatment: A journey in progress
Cho, S., Yeh, T., Anderson, K. C., & Tai, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1032775 · Cited by 66
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Jr., Baljević, M., Baz, R., Campagnaro, E. L., Costello, C. L., D'Angelo, C. R., Derman, B. A., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0023 · Cited by 70
Elotuzumab for the treatment of multiple myeloma
Wang, Y., Sanchez, L. J., Siegel, D. S. D., & Wang, M. L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0284-z · Cited by 66
Self-citationKazandjian, D. G., & Landgren, O. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.008 · Cited by 65
“This additional indication was based on the ASPIRE and APEX trials.(16,17) In ASPIRE, PFS in the carfilzomib, lenalidomide, and dexamethasone arm was significantly improved (median, 26.”
Bringhen, S., Milan, A., D’Agostino, M., Ferri, C., Wäsch, R., Gay, F., Larocca, A., Offidani, M., Zweegman, S., Terpos, E., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12882 · Cited by 65
“dexamethasone, based on the randomized trials ASPIRE [1] and ENDEAVOR [2].”
MethodInfluentialSelf-citationSwan, D., Rocci, A., Bradbury, C. A., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15684 · Cited by 68
The Danish National Multiple Myeloma Registry
Gimsing, P., Holmström, M. O., Klausen, T., Andersen, N. F., Gregersen, H., Pedersen, R. S., Plesner, T., Pedersen, P. T., Frederiksen, M., Frølund, U. C., et al. (2016) · Clinical Epidemiology · doi:10.2147/clep.s99463 · Cited by 64
Gene Expression Profiles in Myeloma: Ready for the Real World?
Szalat, R. E., Avet‐Loiseau, H., & Munshi, N. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0867 · Cited by 66
Pegourié, B., Karlin, L., Benboubker, L., Orsini‐Piocelle, F., Tiab, M., Auger‐Quittet, S., Rodon, P., Royer, B., Leleu, X. P., Bareau, B., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25459 · Cited by 67
The emerging therapeutic landscape of relapsed/refractory multiple myeloma
Tanenbaum, B., Miett, T., & Patel, S. A. (2022) · Annals of Hematology · doi:10.1007/s00277-022-05058-5 · Cited by 66
Ixazomib for the treatment of multiple myeloma
Richardson, P. G. G., Zweegman, S., O’Donnell, E., Laubach, J. P., Raje, N. S., Voorhees, P. M., Ferrari, R. H., Skácel, T., Kumar, S. K., & Lonial, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528229 · Cited by 65
“appear to result in similar rates of PN [55,56].”
BackgroundResult
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.